Small molecule · Inhibitor of KRAS G12D mutant protein (KRAS) · developed by Incyte
INCB161734 is an orally bioavailable inhibitor that specifically binds the oncogenic KRAS G12D mutant protein, preventing its signaling and activation of downstream survival pathways. It is studied in solid tumors, including pancreatic neoplasms.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07522073 | Phase 3 | Solid Tumors | Recruiting | INCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Tumors
See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INCY catalysts and pipeline →